Quick Answer
Entrada Therapeutics, Inc. reported R&D Expense of $142.27 million for fiscal year 2025.
Entrada Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $142.27M | +13.5% |
| 2024 | $125.31M | +25.5% |
| 2023 | $99.88M | +50.0% |
| 2022 | $66.61M | +85.4% |
| 2021 | $35.93M | +70.2% |
| 2020 | $21.10M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $38.36M | +22.7% | +1.3% |
| June 30, 2025 | $37.88M | +18.2% | +18.1% |
| March 31, 2025 | $32.07M | +12.1% | +2.6% |
| September 30, 2024 | $31.26M | +40.9% | -2.4% |
| June 30, 2024 | $32.03M | +21.8% | +12.0% |
| March 31, 2024 | $28.61M | +23.8% | +28.9% |
| September 30, 2023 | $22.19M | +17.1% | -15.6% |
| June 30, 2023 | $26.30M | +61.9% | +13.8% |
- Entrada Therapeutics, Inc. showed an increase of +13.5% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Entrada Therapeutics, Inc.’s r&d expense has grown by 574.2% (from $21.10 million to $142.27 million).
- The most recent figure is from Entrada Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: